George M Ramzy
Overview
Explore the profile of George M Ramzy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
82
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ramzy G, Meister I, Rudaz S, Boccard J, Nowak-Sliwinska P
Int J Mol Sci
. 2025 Feb;
26(3).
PMID: 39940937
Chronic drug treatment can alter the lipidome of cancer cells, potentially leading to significant biological changes, such as drug resistance or increased tumor aggressiveness. This study examines the lipidome profiles...
2.
Challenges in validation of combination treatment strategies for CRC using patient-derived organoids
Benboubker V, Ramzy G, Jacobs S, Nowak-Sliwinska P
J Exp Clin Cancer Res
. 2024 Sep;
43(1):259.
PMID: 39261955
Patient-derived organoids (PDOs) established from tissues from various tumor types gave the foundation of ex vivo models to screen and/or validate the activity of many cancer drug candidates. Due to...
3.
Ramzy G, Norkin M, Koessler T, Voirol L, Tihy M, Hany D, et al.
J Exp Clin Cancer Res
. 2023 Apr;
42(1):79.
PMID: 37013646
Background: We propose a new approach for designing personalized treatment for colorectal cancer (CRC) patients, by combining ex vivo organoid efficacy testing with mathematical modeling of the results. Methods: The...
4.
Ramzy G, Boschung L, Koessler T, Delucinge-Vivier C, Docquier M, McKee T, et al.
Cancers (Basel)
. 2022 Oct;
14(19).
PMID: 36230735
FOLFOXIRI, i.e., the combination of folinic acid, 5-fluorouracil, oxaliplatin, and irinotecan, is a first-line treatment for colorectal carcinoma (CRC), yet non-personalized and aggressive. In this study, to mimic the clinical...
5.
Zoetemelk M, Ramzy G, Rausch M, Koessler T, van Beijnum J, Weiss A, et al.
Mol Oncol
. 2020 Oct;
14(11):2894-2919.
PMID: 33021054
The current standard of care for colorectal cancer (CRC) is a combination of chemotherapeutics, often supplemented with targeted biological drugs. An urgent need exists for improved drug efficacy and minimized...
6.
Zoetemelk M, Ramzy G, Rausch M, Nowak-Sliwinska P
Molecules
. 2020 Jun;
25(11).
PMID: 32512790
The combination of folinic acid, 5-fluorouracil, oxaliplatin and/or irinotecan (FOLFOXIRI) is the standard of care for metastatic colorectal cancer (CRC). This strategy inhibits tumor growth but provokes drug resistance and...
7.
Ramzy G, Koessler T, Ducrey E, McKee T, Ris F, Buchs N, et al.
Cancers (Basel)
. 2020 Jun;
12(6).
PMID: 32486365
Lack of relevant preclinical models that reliably recapitulate the complexity and heterogeneity of human cancer has slowed down the development and approval of new anti-cancer therapies. Even though two-dimensional in...
8.
Weiss A, Le Roux-Bourdieu M, Zoetemelk M, Ramzy G, Rausch M, Harry D, et al.
Cancers (Basel)
. 2019 Oct;
11(10).
PMID: 31652588
A major limitation of clinically used cancer drugs is the lack of specificity resulting in toxicity. To address this, we performed a phenotypically-driven screen to identify optimal multidrug combinations acting...